Подписаться
Federico Rojo
Federico Rojo
Fundacion Jimenez Diaz
Подтвержден адрес электронной почты в домене fjd.es
Название
Процитировано
Процитировано
Год
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ...
Cancer research 66 (3), 1500-1508, 2006
29702006
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, ...
The Journal of clinical investigation 118 (9), 3065-3074, 2008
16622008
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
MA Molina, J Codony-Servat, J Albanell, F Rojo, J Arribas, J Baselga
Cancer research 61 (12), 4744-4749, 2001
10632001
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...
Journal of the National Cancer Institute 99 (8), 628-638, 2007
10232007
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …
J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ...
Journal of clinical oncology 20 (21), 4292-4302, 2002
10172002
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
I Shin, FM Yakes, F Rojo, NY Shin, AV Bakin, J Baselga, CL Arteaga
Nature medicine 8 (10), 1145-1152, 2002
9892002
A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition
T Vincent, EPA Neve, JR Johnson, A Kukalev, F Rojo, J Albanell, ...
Nature cell biology 11 (8), 943-950, 2009
7742009
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non–small-cell lung cancer and other solid …
RS Herbst, AM Maddox, ML Rothenberg, EJ Small, EH Rubin, J Baselga, ...
Journal of Clinical Oncology 20 (18), 3815-3825, 2002
7522002
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311-335, 2017
6652017
Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, ...
Journal of Clinical Oncology 26 (10), 1603-1610, 2008
6372008
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
J Albanell, F Rojo, S Averbuch, A Feyereislova, JM Mascaro, R Herbst, ...
Journal of Clinical Oncology 20 (1), 110-124, 2002
6342002
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235-251, 2017
5972017
High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
A Bruna, RS Darken, F Rojo, A Ocaña, S Peñuelas, A Arias, R Paris, ...
Cancer cell 11 (2), 147-160, 2007
5792007
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
A O'Donnell, S Faivre, HA Burris III, D Rea, V Papadimitrakopoulou, ...
Journal of Clinical Oncology 26 (10), 1588-1595, 2008
5592008
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga, J Albanell, A Ruiz, A Lluch, P Gascón, V Guillém, S González, ...
J Clin Oncol 23 (23), 5323-5333, 2005
5132005
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in …
MV Dieci, N Radosevic-Robin, S Fineberg, G Van den Eynden, N Ternes, ...
Seminars in cancer biology 52, 16-25, 2018
411*2018
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor α expression in head and neck squamous carcinoma …
J Albanell, J Codony-Servat, F Rojo, JM Del Campo, S Sauleda, J Anido, ...
Cancer research 61 (17), 6500-6510, 2001
3932001
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor …
U Vanhoefer, M Tewes, F Rojo, O Dirsch, N Schleucher, O Rosen, ...
Journal of Clinical Oncology 22 (1), 175-184, 2004
3762004
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225) superiority over …
P Matar, F Rojo, R Cassia, G Moreno-Bueno, S Di Cosimo, J Tabernero, ...
Clinical cancer research 10 (19), 6487-6501, 2004
3672004
TACE is required for the activation of the EGFR by TGF‐α in tumors
M Borrell‐Pagès, F Rojo, J Albanell, J Baselga, J Arribas
The EMBO journal, 2003
3582003
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20